<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559646</url>
  </required_header>
  <id_info>
    <org_study_id>PEGASUS2020</org_study_id>
    <nct_id>NCT04559646</nct_id>
  </id_info>
  <brief_title>Application of the &quot;Haemoblock&quot; in Pacemaker Patients</brief_title>
  <official_title>Application of the Haemostatic Solution &quot;Haemoblock&quot; to Reduce the Risk of Pacemaker Pocket Hematoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ryazan State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ryazan State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pocket hematoma is a known complication of pacemaker (PM) implantation. Pocket hematoma is&#xD;
      accompanied by a local discomfort associated with the infiltration of subcutaneous tissue. In&#xD;
      some cases, this complication requires repeated surgical revisions, which increases the risk&#xD;
      of infection, and increases the duration of a hospital stay. The search for ways to prevent&#xD;
      bleeding from the PM pocket is of great practical interest. This question is especially acute&#xD;
      in relation to patients who are constantly on anticoagulation and/or antiplatelet therapy. A&#xD;
      number of authors propose to carry out complete or partial cancellation of these drugs for&#xD;
      the period before surgery and in the early postoperative period. In our opinion, this&#xD;
      approach in most cases carries a potential risk to the health of patients, especially in the&#xD;
      case of patients who have previously undergone surgical correction of valve insufficiency&#xD;
      and/or who have undergone percutaneous endovascular interventions.&#xD;
&#xD;
      The use of local hemostatic drugs is one of the promising directions for increasing the&#xD;
      efficiency of intraoperative hemostasis. The haemostatic solution &quot;Haemoblock&quot; has shown its&#xD;
      hemostatic potential in general surgical practice. The possibilities of &quot;Haemoblock&quot; in the&#xD;
      prevention of pocket hematoma have not been studied. The hemostatic effect of &quot;Haemoblock&quot; is&#xD;
      achieved within 1-2 minutes due to the formation of a clot with blood plasma proteins, first&#xD;
      of all with albumin. As a result of the action of the &quot;Haemoblock&quot;, a strong polymethacrylate&#xD;
      membrane is formed on the surface of the wound, which, among other things, has a bactericidal&#xD;
      effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      –ê multicenter research trial will be conducted at 6 medical centers:&#xD;
&#xD;
        -  Ryazan State Medical University (Ryazan);&#xD;
&#xD;
        -  Federal State Budgetary Institution &quot;Federal Center for Cardiovascular Surgery&quot; of the&#xD;
           Ministry of Health of the Russian Federation (Astrakhan);&#xD;
&#xD;
        -  Federal State Budgetary Institution &quot;Federal Center for Cardiovascular Surgery&quot; of the&#xD;
           Ministry of Health of the Russian Federation (Penza);&#xD;
&#xD;
        -  Federal State Budgetary Institution &quot;Federal Center for Cardiovascular Surgery&quot; of the&#xD;
           Ministry of Health of the Russian Federation (Chelyabinsk);&#xD;
&#xD;
        -  Federal State Budgetary Institution &quot;Federal Center for Cardiovascular Surgery&quot; of the&#xD;
           Ministry of Health of the Russian Federation (Kaliningrad);&#xD;
&#xD;
        -  Federal State Budgetary Institution &quot;Federal Center for Cardiovascular Surgery&quot; of the&#xD;
           Ministry of Health of the Russian Federation (Khabarovsk).&#xD;
&#xD;
      Haemostatic solution &quot;Haemoblock&quot; provided by Autonomous non-profit organization &quot;MOSCOW&#xD;
      REGIONAL SCIENTIFIC RESEARCH INSTITUTE OF BLOOD&quot;.&#xD;
&#xD;
      The study will include 200 patients with indications for pacemaker implantation&#xD;
      (atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired&#xD;
      atrioventricular conduction or other).&#xD;
&#xD;
      Before starting the study, the patient must give written consent to participate in this study&#xD;
      after familiarizing him with the purpose and rules of the clinical study.&#xD;
&#xD;
      All patients during randomisation will be divided into 2 groups:&#xD;
&#xD;
      Group A &quot;Haemoblock&quot; - 100 patients. Haemostatic solution &quot;Haemoblock&quot; will be used after&#xD;
      pocket formation during pacemaker implantation (sterile gauze swabs are soaked in 15 ml of&#xD;
      &quot;Haemoblock&quot; solution and applied in pacemaker pocket, then pacemaker pocket will be&#xD;
      irrigated with 5 ml of &quot;Haemoblock&quot; solution without rinsing).&#xD;
&#xD;
      Group B &quot;Control&quot; - 100 patients. Same procedure will be performed with saline solution in&#xD;
      this group.&#xD;
&#xD;
      Before surgery blood sampling, echocardiography will be performed in all patients.&#xD;
&#xD;
      3-5 days after surgery ultrasound of pacemaker pocket will be performed in all patients.&#xD;
&#xD;
      The observation period for patients will be 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The presence of free fluid (blood) in the pacemaker pocket in the early postoperative period, diagnosed by ultrasound.</measure>
    <time_frame>Up to 30 days after pacemaker implantation.</time_frame>
    <description>Ultrasound of pacemaker pocket to diagnose pocket hematoma will be performed in all patients. The presence of a hematoma (fluid) in the pacemaker pocket before the ultrasound can be verified after examination by the surgeon by the detection of palpable infiltration, smoothing the pacemaker contour, the presence of a fluctuation effect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drainage installation during surgery.</measure>
    <time_frame>During surgery.</time_frame>
    <description>Installation of a drainage system during pacemaker implantation for draining hematoma after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematoma drainage duration.</measure>
    <time_frame>Up to 7 days after pacemaker implantation.</time_frame>
    <description>Duration of hematoma drainage after pacemaker implantation if installed during surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imbibition of soft tissues near pacemaker pocket.</measure>
    <time_frame>Up to 30 days after pacemaker implantation.</time_frame>
    <description>Imbibition of soft tissues around pacemaker pocket detected on physical examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exceeding the average length of hospital stay.</measure>
    <time_frame>Up to 30 days after pacemaker implantation.</time_frame>
    <description>Exceeding the average length (7 days) of hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacemaker implantation complications and cardiac events (stroke, transient ischemic attack, bleeding, pericarditis, cardiac tamponade, infection).</measure>
    <time_frame>Up to 30 days after pacemaker implantation.</time_frame>
    <description>Pacemaker implantation complications and cardiac events (stroke, transient ischemic attack, bleeding, pericarditis, cardiac tamponade, infection) development during observation period.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hematoma Postoperative</condition>
  <arm_group>
    <arm_group_label>Group A &quot;Haemoblock&quot;</arm_group_label>
    <description>100 patients. Haemostatic solution &quot;Haemoblock&quot; will be used after pocket formation during pacemaker implantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B &quot;Control&quot;</arm_group_label>
    <description>100 patients. Saline solution will be used after pocket formation during pacemaker implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pacemaker implantation</intervention_name>
    <description>Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.</description>
    <arm_group_label>Group A &quot;Haemoblock&quot;</arm_group_label>
    <arm_group_label>Group B &quot;Control&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haemostatic solution &quot;Haemoblock&quot; application</intervention_name>
    <description>Haemostatic solution &quot;Haemoblock&quot; will be used after pocket formation during pacemaker implantation.</description>
    <arm_group_label>Group A &quot;Haemoblock&quot;</arm_group_label>
    <other_name>&quot;Haemoblock&quot; application</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution application</intervention_name>
    <description>Saline solution will be used after pocket formation during pacemaker implantation.</description>
    <arm_group_label>Group B &quot;Control&quot;</arm_group_label>
    <other_name>Saline application</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasound of pacemaker pocket</intervention_name>
    <description>Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.</description>
    <arm_group_label>Group A &quot;Haemoblock&quot;</arm_group_label>
    <arm_group_label>Group B &quot;Control&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.</description>
    <arm_group_label>Group A &quot;Haemoblock&quot;</arm_group_label>
    <arm_group_label>Group B &quot;Control&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Heart ultrasound examination for left ventricular ejection fraction measurement.</description>
    <arm_group_label>Group A &quot;Haemoblock&quot;</arm_group_label>
    <arm_group_label>Group B &quot;Control&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        200 patients with indications for pacemaker implantation (atrioventricular block, sick&#xD;
        sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  availability of informed consent of the patient to participate in the study;&#xD;
&#xD;
          -  men and women aged 40-85 years with indications for pacemaker implantation, taking&#xD;
             oral anticoagulants before surgery for at least 7 days;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypoalbuminemia;&#xD;
&#xD;
          -  known contraindications for the study haemostatic solution &quot;Haemoblock&quot;;&#xD;
&#xD;
          -  severe arterial hypertension: Systolic blood pressure ‚â• 200 mmHg and/or Diastolic&#xD;
             blood pressure ‚â• 110 mmHg;&#xD;
&#xD;
          -  unstable forms of ischemic heart disease;&#xD;
&#xD;
          -  hemostasis disorders in the number of platelets, prothrombin, fibrinogen levels, or&#xD;
             International Normalised Ratio above 3.0&#xD;
&#xD;
          -  LVEF according to Simpson &lt;35%;&#xD;
&#xD;
          -  the period of pregnancy and lactation;&#xD;
&#xD;
          -  chronic renal failure: creatinine clearance less than 40 ml/min;&#xD;
&#xD;
          -  hemoglobin level &lt;90 g/l;&#xD;
&#xD;
          -  participation in another study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor A. Suchkov, MD, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ryazan State Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Igor A. Suchkov, MD, DSc</last_name>
    <phone>+7-903-836-2417</phone>
    <email>suchkov_med@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vladislav O. Povarov, MD, PhD</last_name>
    <phone>+7-915-602-74-78</phone>
    <email>povarov.vladislav@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ryazan State Medical University</name>
      <address>
        <city>Ryazan'</city>
        <state>Ryazan</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor A. Suchkov, MD, DSc</last_name>
      <phone>+7-903-836-2417</phone>
      <email>suchkov_med@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Vladislav O. Povarov, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac implantable electronic devices</keyword>
  <keyword>Pacing</keyword>
  <keyword>Pocket hematoma</keyword>
  <keyword>Haemorrhagic complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Basic demographic data, including sex, age, and ethnicity are to be shared if allowed by the privacy policy.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

